Testen van de toevoeging van BMS-986016 (Relatlimab) aan de gebruikelijke immunotherapie na initiële behandeling voor recidiverende of gemetastaseerde nasofaryngeale kanker
Een gerandomiseerde fase II-studie van Nivolumab versus nivolumab en BMS-986016 (Relatlimab) als onderhoudsbehandeling na eerstelijnsbehandeling met platina-gemcitabine-nivolumab voor patiënten met Epstein-Barr-virus-geassocieerd recidiverend/gemetastaseerd nasofarynxcarcinoom (REMAIN)
This phase II trial tests the addition of BMS-986016 (relatlimab) to the usual immunotherapy after initial treatment for nasopharyngeal cancer that has come back after a period of improvement (recurrent) or that has spread from where it first started (primary site) to other places in the body (metastatic). Relatlimab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. The usual approach of treatment is initial treatment with chemotherapy such as the combination of cisplatin (or carboplatin) and gemcitabine, along with immunotherapy such as nivolumab. After the initial treatment is finished, patients may continue to receive additional immunotherapy. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Gemcitabine is a chemotherapy drug that blocks the cells from making deoxyribonucleic acid (DNA) and may kill cancer cells. Giving BMS-986016 in addition to the usual immunotherapy after initial treatment may extend the time without the tumor cells growing or spreading longer than the usual approach in patients with recurrent or metastatic nasopharyngeal cancer.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
PRIMARY OBJECTIVE:
I. To determine if adding BMS-986016 (relatlimab) to nivolumab maintenance therapy shows a signal of improved progression-free survival (PFS) according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 in patients who do not progress following treatment with platinum-gemcitabine-nivolumab combination in the first-line treatment of recurrent and/or metastatic nasopharyngeal carcinoma (R/M NPC).
SECONDARY OBJECTIVES:
I. To determine if adding BMS-986016 (relatlimab) to nivolumab maintenance improves overall survival (OS) compared to nivolumab maintenance alone.
II. To compare patterns of failure (local-regional relapse and distant metastasis) between treatment arms.
III. To determine if adding BMS-986016 (relatlimab) to nivolumab maintenance improves objective response, duration of response, and disease control rate compared to nivolumab maintenance alone.
IV. To evaluate the tolerability of nivolumab-BMS-986016 (relatlimab) maintenance and assess and compare toxicity between arms based on the Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0) criteria.
V. To evaluate baseline plasma Epstein-Barr virus (EBV) DNA (< 2000 copies/mL versus [vs.] >= 2000 copies/mL) as a prognostic biomarker.
VI. To validate post-induction plasma EBV DNA (detectable [>= 1 copies/mL] vs. undetectable [0 copies/mL]) as a prognostic biomarker.
EXPLORATORY OBJECTIVES:
I. To collect blood and tissue specimens for future translational science studies.
II. To assess post-induction plasma EBV DNA (detectable [>= 1 copies/mL] vs. undetectable [0 copies/mL]) as a predictive biomarker.
OUTLINE:
INDUCTION THERAPY: Patients receive nivolumab intravenously (IV) over 30 minutes on day 1 of each cycle, cisplatin IV or carboplatin IV over 30-60 minutes on day 1 of each cycle and gemcitabine IV over 30 minutes on days 1 and 8 of each cycle. Cycles repeat every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo computed tomography (CT) or magnetic resonance imaging (MRI) and blood sample collection during screening and on study.
MAINTENANCE THERAPY: Patients who do not progress radiologically are randomized to 1 of 2 arms.
ARM I: Patients receive nivolumab IV over 30 minutes. Cycles repeat every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI on study. Patients also undergo positron emission tomography (PET)/CT or bone scan as clinically indicated.
ARM II: Patients receive nivolumab IV over 30 minutes and relatlimab IV over 30-90 minutes. Cycles repeat every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI on study. Patients also undergo PET/CT or bone scan as clinically indicated.
After completion of study treatment, patients are followed up every 4 months for 2 years, every 6 months in years 3-5, and then annually.
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
Contacten en locaties
Studie Locaties
-
-
Victoria
-
Melbourne, Victoria, Australië, 3000
- Werving
- Peter MacCallum Cancer Centre
-
Contact:
- Site Public Contact
- Telefoonnummer: 61 3 9656 1521
-
Hoofdonderzoeker:
- Danny Rischin
-
-
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2M9
- Werving
- University Health Network-Princess Margaret Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 416-946-4501
- E-mail: clinical.trials@uhn.on.ca
-
Hoofdonderzoeker:
- Enrique Sanz Garcia
-
-
-
-
-
Shatin, Hongkong
- Werving
- Chinese University of Hong Kong-Prince of Wales Hospital
-
Contact:
- Site Public Contact
- E-mail: ccrb@cuhk.edu.hk
-
Hoofdonderzoeker:
- Brigette B. Ma
-
-
-
-
-
Singapore, Singapore, 119074
- Werving
- National University Hospital Singapore
-
Contact:
- Site Public Contact
- E-mail: horg@nuhs.edu.sg
-
Hoofdonderzoeker:
- Boon C. Goh
-
Singapore, Singapore, 168583
- Werving
- National Cancer Centre Singapore
-
Contact:
- Site Public Contact
- Telefoonnummer: 65 6225 5655
- E-mail: cancerhelpline@nccs.com.sg
-
Hoofdonderzoeker:
- Wan Teck D. Lim
-
-
-
-
California
-
Dublin, California, Verenigde Staten, 94568
- Werving
- Kaiser Permanente Dublin
-
Contact:
- Site Public Contact
- Telefoonnummer: 877-642-4691
-
Hoofdonderzoeker:
- Jed A. Katzel
-
Fremont, California, Verenigde Staten, 94538
- Werving
- Kaiser Permanente-Fremont
-
Contact:
- Site Public Contact
- Telefoonnummer: 877-642-4691
- E-mail: Kpoct@kp.org
-
Hoofdonderzoeker:
- Jed A. Katzel
-
Fresno, California, Verenigde Staten, 93720
- Werving
- Kaiser Permanente-Fresno
-
Contact:
- Site Public Contact
- Telefoonnummer: 877-642-4691
- E-mail: Kpoct@kp.org
-
Hoofdonderzoeker:
- Jed A. Katzel
-
Fresno, California, Verenigde Staten, 93720
- Werving
- Kaiser Permanente Fresno Orchard Plaza
-
Hoofdonderzoeker:
- Jed A. Katzel
-
Contact:
- Site Public Contact
- Telefoonnummer: 833-574-2273
-
Los Angeles, California, Verenigde Staten, 90033
- Werving
- USC / Norris Comprehensive Cancer Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 323-865-0451
-
Hoofdonderzoeker:
- Jacob S. Thomas
-
Los Angeles, California, Verenigde Staten, 90020
- Werving
- Keck Medicine of USC Koreatown
-
Contact:
- Site Public Contact
- Telefoonnummer: 213-388-0908
-
Hoofdonderzoeker:
- Jacob S. Thomas
-
Los Angeles, California, Verenigde Staten, 90033
- Werving
- Los Angeles General Medical Center
-
Hoofdonderzoeker:
- Jacob S. Thomas
-
Contact:
- Site Public Contact
- Telefoonnummer: 323-865-0451
- E-mail: uscnorrisinfo@med.usc.edu
-
Modesto, California, Verenigde Staten, 95356
- Werving
- Kaiser Permanente-Modesto
-
Contact:
- Site Public Contact
- Telefoonnummer: 877-642-4691
- E-mail: Kpoct@kp.org
-
Hoofdonderzoeker:
- Jed A. Katzel
-
Modesto, California, Verenigde Staten, 95356
- Werving
- Kaiser Permanente- Modesto MOB II
-
Contact:
- Site Public Contact
- Telefoonnummer: 877-642-4691
-
Hoofdonderzoeker:
- Jed A. Katzel
-
Newport Beach, California, Verenigde Staten, 92663
- Werving
- USC Norris Oncology/Hematology-Newport Beach
-
Contact:
- Site Public Contact
- Telefoonnummer: 323-865-0451
-
Hoofdonderzoeker:
- Jacob S. Thomas
-
Oakland, California, Verenigde Staten, 94611
- Werving
- Kaiser Permanente-Oakland
-
Contact:
- Site Public Contact
- Telefoonnummer: 877-642-4691
- E-mail: Kpoct@kp.org
-
Hoofdonderzoeker:
- Jed A. Katzel
-
Palo Alto, California, Verenigde Staten, 94304
- Werving
- Stanford Cancer Institute Palo Alto
-
Hoofdonderzoeker:
- Alexander D. Colevas
-
Contact:
- Site Public Contact
- Telefoonnummer: 650-498-7061
- E-mail: cancertrialsinfo@stanford.edu
-
Roseville, California, Verenigde Staten, 95661
- Werving
- Kaiser Permanente-Roseville
-
Contact:
- Site Public Contact
- Telefoonnummer: 877-642-4691
- E-mail: Kpoct@kp.org
-
Hoofdonderzoeker:
- Jed A. Katzel
-
Sacramento, California, Verenigde Staten, 95817
- Werving
- University of California Davis Comprehensive Cancer Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 916-734-3089
-
Hoofdonderzoeker:
- Siao-Yi Wang
-
Sacramento, California, Verenigde Staten, 95814
- Werving
- Kaiser Permanente Downtown Commons
-
Hoofdonderzoeker:
- Jed A. Katzel
-
Contact:
- Site Public Contact
- Telefoonnummer: 877-642-4691
- E-mail: kpoct@kp.org
-
Sacramento, California, Verenigde Staten, 95823
- Werving
- Kaiser Permanente-South Sacramento
-
Contact:
- Site Public Contact
- Telefoonnummer: 877-642-4691
- E-mail: Kpoct@kp.org
-
Hoofdonderzoeker:
- Jed A. Katzel
-
San Francisco, California, Verenigde Staten, 94115
- Werving
- Kaiser Permanente-San Francisco
-
Contact:
- Site Public Contact
- Telefoonnummer: 877-642-4691
- E-mail: Kpoct@kp.org
-
Hoofdonderzoeker:
- Jed A. Katzel
-
San Jose, California, Verenigde Staten, 95119
- Werving
- Kaiser Permanente-Santa Teresa-San Jose
-
Contact:
- Site Public Contact
- Telefoonnummer: 877-642-4691
- E-mail: Kpoct@kp.org
-
Hoofdonderzoeker:
- Jed A. Katzel
-
San Leandro, California, Verenigde Staten, 94577
- Werving
- Kaiser Permanente San Leandro
-
Contact:
- Site Public Contact
- Telefoonnummer: 877-642-4691
- E-mail: Kpoct@kp.org
-
Hoofdonderzoeker:
- Jed A. Katzel
-
San Rafael, California, Verenigde Staten, 94903
- Werving
- Kaiser San Rafael-Gallinas
-
Contact:
- Site Public Contact
- Telefoonnummer: 877-642-4691
- E-mail: Kpoct@kp.org
-
Hoofdonderzoeker:
- Jed A. Katzel
-
Santa Clara, California, Verenigde Staten, 95051
- Werving
- Kaiser Permanente Medical Center - Santa Clara
-
Contact:
- Site Public Contact
- Telefoonnummer: 877-642-4691
- E-mail: Kpoct@kp.org
-
Hoofdonderzoeker:
- Jed A. Katzel
-
Santa Rosa, California, Verenigde Staten, 95403
- Werving
- Kaiser Permanente-Santa Rosa
-
Contact:
- Site Public Contact
- Telefoonnummer: 877-642-4691
- E-mail: Kpoct@kp.org
-
Hoofdonderzoeker:
- Jed A. Katzel
-
South San Francisco, California, Verenigde Staten, 94080
- Werving
- Kaiser Permanente-South San Francisco
-
Contact:
- Site Public Contact
- Telefoonnummer: 877-642-4691
- E-mail: Kpoct@kp.org
-
Hoofdonderzoeker:
- Jed A. Katzel
-
Vallejo, California, Verenigde Staten, 94589
- Werving
- Kaiser Permanente-Vallejo
-
Contact:
- Site Public Contact
- Telefoonnummer: 877-642-4691
- E-mail: Kpoct@kp.org
-
Hoofdonderzoeker:
- Jed A. Katzel
-
Walnut Creek, California, Verenigde Staten, 94596
- Werving
- Kaiser Permanente-Walnut Creek
-
Contact:
- Site Public Contact
- Telefoonnummer: 877-642-4691
- E-mail: Kpoct@kp.org
-
Hoofdonderzoeker:
- Jed A. Katzel
-
-
Georgia
-
Atlanta, Georgia, Verenigde Staten, 30308
- Werving
- Emory University Hospital Midtown
-
Contact:
- Site Public Contact
- Telefoonnummer: 888-946-7447
-
Hoofdonderzoeker:
- Conor E. Steuer
-
-
Hawaii
-
Honolulu, Hawaii, Verenigde Staten, 96819
- Werving
- Kaiser Permanente Moanalua Medical Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 808-432-5195
- E-mail: shelley.a.clark@kp.org
-
Hoofdonderzoeker:
- Jed A. Katzel
-
-
Idaho
-
Boise, Idaho, Verenigde Staten, 83706
- Geschorst
- Saint Alphonsus Cancer Care Center-Boise
-
Caldwell, Idaho, Verenigde Staten, 83605
- Geschorst
- Saint Alphonsus Cancer Care Center-Caldwell
-
Coeur d'Alene, Idaho, Verenigde Staten, 83814
- Werving
- Kootenai Health - Coeur d'Alene
-
Hoofdonderzoeker:
- John M. Schallenkamp
-
Contact:
- Site Public Contact
- Telefoonnummer: 406-969-6060
- E-mail: mccinfo@mtcancer.org
-
Nampa, Idaho, Verenigde Staten, 83687
- Geschorst
- Saint Alphonsus Cancer Care Center-Nampa
-
Post Falls, Idaho, Verenigde Staten, 83854
- Werving
- Kootenai Clinic Cancer Services - Post Falls
-
Hoofdonderzoeker:
- John M. Schallenkamp
-
Contact:
- Site Public Contact
- Telefoonnummer: 406-969-6060
- E-mail: mccinfo@mtcancer.org
-
Sandpoint, Idaho, Verenigde Staten, 83864
- Werving
- Kootenai Clinic Cancer Services - Sandpoint
-
Hoofdonderzoeker:
- John M. Schallenkamp
-
Contact:
- Site Public Contact
- Telefoonnummer: 406-969-6060
- E-mail: mccinfo@mtcancer.org
-
-
Illinois
-
Chicago, Illinois, Verenigde Staten, 60612
- Actief, niet wervend
- University of Illinois
-
Chicago, Illinois, Verenigde Staten, 60611
- Werving
- Northwestern University
-
Contact:
- Site Public Contact
- Telefoonnummer: 312-695-1301
- E-mail: cancer@northwestern.edu
-
Hoofdonderzoeker:
- Jochen H. Lorch
-
Danville, Illinois, Verenigde Staten, 61832
- Werving
- Carle at The Riverfront
-
Hoofdonderzoeker:
- Prem Sobti
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-446-5532
- E-mail: Research@Carle.com
-
DeKalb, Illinois, Verenigde Staten, 60115
- Werving
- Northwestern Medicine Cancer Center Kishwaukee
-
Contact:
- Site Public Contact
- Telefoonnummer: 630-352-5360
- E-mail: Donald.Smith3@nm.org
-
Hoofdonderzoeker:
- Jochen H. Lorch
-
Effingham, Illinois, Verenigde Staten, 62401
- Werving
- Carle Physician Group-Effingham
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-446-5532
- E-mail: Research@carle.com
-
Hoofdonderzoeker:
- Prem Sobti
-
Geneva, Illinois, Verenigde Staten, 60134
- Werving
- Northwestern Medicine Cancer Center Delnor
-
Contact:
- Site Public Contact
- Telefoonnummer: 630-352-5360
- E-mail: Donald.Smith3@nm.org
-
Hoofdonderzoeker:
- Jochen H. Lorch
-
Glenview, Illinois, Verenigde Staten, 60026
- Werving
- Northwestern Medicine Glenview Outpatient Center
-
Hoofdonderzoeker:
- Jochen H. Lorch
-
Contact:
- Site Public Contact
- Telefoonnummer: 312-695-1102
-
Grayslake, Illinois, Verenigde Staten, 60030
- Werving
- Northwestern Medicine Grayslake Outpatient Center
-
Hoofdonderzoeker:
- Jochen H. Lorch
-
Contact:
- Site Public Contact
- Telefoonnummer: 312-695-1102
-
Lake Forest, Illinois, Verenigde Staten, 60045
- Werving
- Northwestern Medicine Lake Forest Hospital
-
Contact:
- Site Public Contact
- E-mail: cancertrials@northwestern.edu
-
Hoofdonderzoeker:
- Jochen H. Lorch
-
Mattoon, Illinois, Verenigde Staten, 61938
- Werving
- Carle Physician Group-Mattoon/Charleston
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-446-5532
- E-mail: Research@carle.com
-
Hoofdonderzoeker:
- Prem Sobti
-
Orland Park, Illinois, Verenigde Staten, 60462
- Werving
- Northwestern Medicine Orland Park
-
Hoofdonderzoeker:
- Jochen H. Lorch
-
Contact:
- Site Public Contact
- E-mail: nctnprogram_rhlccc@northwestern.edu
-
Urbana, Illinois, Verenigde Staten, 61801
- Werving
- Carle Cancer Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-446-5532
- E-mail: Research@carle.com
-
Hoofdonderzoeker:
- Prem Sobti
-
Warrenville, Illinois, Verenigde Staten, 60555
- Werving
- Northwestern Medicine Cancer Center Warrenville
-
Contact:
- Site Public Contact
- Telefoonnummer: 630-352-5360
- E-mail: Donald.Smith3@nm.org
-
Hoofdonderzoeker:
- Jochen H. Lorch
-
-
Iowa
-
Ankeny, Iowa, Verenigde Staten, 50023
- Werving
- UI Health Care Mission Cancer and Blood - Ankeny Clinic
-
Contact:
- Site Public Contact
- Telefoonnummer: 515-241-3305
-
Hoofdonderzoeker:
- Seema Harichand-Herdt
-
Carroll, Iowa, Verenigde Staten, 51401
- Werving
- Saint Anthony Regional Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 515-689-7658
- E-mail: sbenson@iora.org
-
Hoofdonderzoeker:
- Seema Harichand-Herdt
-
Clive, Iowa, Verenigde Staten, 50325
- Werving
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Contact:
- Site Public Contact
- Telefoonnummer: 515-241-3305
-
Hoofdonderzoeker:
- Seema Harichand-Herdt
-
Council Bluffs, Iowa, Verenigde Staten, 51503
- Geschorst
- Heartland Oncology and Hematology LLP
-
Council Bluffs, Iowa, Verenigde Staten, 51503
- Geschorst
- Methodist Jennie Edmundson Hospital
-
Council Bluffs, Iowa, Verenigde Staten, 51503
- Geschorst
- Nebraska Cancer Specialists/Oncology Hematology West PC - MEJ
-
Des Moines, Iowa, Verenigde Staten, 50314
- Werving
- Broadlawns Medical Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 515-282-2200
-
Hoofdonderzoeker:
- Seema Harichand-Herdt
-
Des Moines, Iowa, Verenigde Staten, 50314
- Werving
- Mercy Medical Center - Des Moines
-
Contact:
- Site Public Contact
- Telefoonnummer: 515-241-3305
-
Hoofdonderzoeker:
- Richard L. Deming
-
Des Moines, Iowa, Verenigde Staten, 50309
- Werving
- Iowa Methodist Medical Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 515-241-6727
-
Hoofdonderzoeker:
- Seema Harichand-Herdt
-
Des Moines, Iowa, Verenigde Staten, 50309
- Werving
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Contact:
- Site Public Contact
- Telefoonnummer: 515-241-3305
-
Hoofdonderzoeker:
- Seema Harichand-Herdt
-
Des Moines, Iowa, Verenigde Staten, 50314
- Werving
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Contact:
- Site Public Contact
- Telefoonnummer: 515-241-3305
-
Hoofdonderzoeker:
- Seema Harichand-Herdt
-
Fort Dodge, Iowa, Verenigde Staten, 50501
- Werving
- UI Healthcare Mission Cancer and Blood - Fort Dodge
-
Hoofdonderzoeker:
- Seema Harichand-Herdt
-
Contact:
- Site Public Contact
- Telefoonnummer: 515-282-2921
- E-mail: trials@missioncancer.com
-
Waukee, Iowa, Verenigde Staten, 50263
- Werving
- UI Health Care Mission Cancer and Blood - Waukee Clinic
-
Contact:
- Site Public Contact
- Telefoonnummer: 515-241-3305
-
Hoofdonderzoeker:
- Seema Harichand-Herdt
-
-
Missouri
-
St Louis, Missouri, Verenigde Staten, 63128
- Werving
- Mercy Hospital South
-
Hoofdonderzoeker:
- Jay W. Carlson
-
Contact:
- Site Public Contact
- Telefoonnummer: 314-525-6042
- E-mail: Danielle.Werle@mercy.net
-
St Louis, Missouri, Verenigde Staten, 63141
- Werving
- Mercy Hospital Saint Louis
-
Hoofdonderzoeker:
- Jay W. Carlson
-
Contact:
- Site Public Contact
- Telefoonnummer: 314-251-7066
-
-
Montana
-
Anaconda, Montana, Verenigde Staten, 59711
- Werving
- Community Hospital of Anaconda
-
Hoofdonderzoeker:
- John M. Schallenkamp
-
Contact:
- Site Public Contact
- Telefoonnummer: 406-969-6060
- E-mail: mccinfo@mtcancer.org
-
Billings, Montana, Verenigde Staten, 59101
- Werving
- Billings Clinic Cancer Center
-
Hoofdonderzoeker:
- John M. Schallenkamp
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-996-2663
- E-mail: research@billingsclinic.org
-
Bozeman, Montana, Verenigde Staten, 59715
- Werving
- Bozeman Health Deaconess Hospital
-
Hoofdonderzoeker:
- John M. Schallenkamp
-
Contact:
- Site Public Contact
- Telefoonnummer: 406-969-6060
- E-mail: mccinfo@mtcancer.org
-
Great Falls, Montana, Verenigde Staten, 59405
- Werving
- Benefis Sletten Cancer Institute
-
Hoofdonderzoeker:
- John M. Schallenkamp
-
Contact:
- Site Public Contact
- Telefoonnummer: 406-969-6060
- E-mail: mccinfo@mtcancer.org
-
Kalispell, Montana, Verenigde Staten, 59901
- Werving
- Logan Health Medical Center
-
Hoofdonderzoeker:
- John M. Schallenkamp
-
Contact:
- Site Public Contact
- Telefoonnummer: 406-969-6060
- E-mail: mccinfo@mtcancer.org
-
Missoula, Montana, Verenigde Staten, 59804
- Werving
- Community Medical Center
-
Hoofdonderzoeker:
- John M. Schallenkamp
-
Contact:
- Site Public Contact
- Telefoonnummer: 406-969-6060
- E-mail: mccinfo@mtcancer.org
-
-
Nebraska
-
Omaha, Nebraska, Verenigde Staten, 68114
- Werving
- Nebraska Cancer Specialists/Oncology Hematology West PC - MECC
-
Contact:
- Site Public Contact
- Telefoonnummer: 402-334-4773
-
Hoofdonderzoeker:
- Yungpo B. Su
-
Omaha, Nebraska, Verenigde Staten, 68114
- Werving
- Nebraska Methodist Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 402-354-5144
-
Hoofdonderzoeker:
- Yungpo B. Su
-
Omaha, Nebraska, Verenigde Staten, 68114
- Geschorst
- Oncology Associates PC
-
-
New Jersey
-
Basking Ridge, New Jersey, Verenigde Staten, 07920
- Werving
- Memorial Sloan Kettering Basking Ridge
-
Hoofdonderzoeker:
- Alan L. Ho
-
Contact:
- Site Public Contact
- Telefoonnummer: 212-639-7592
-
Middletown, New Jersey, Verenigde Staten, 07748
- Werving
- Memorial Sloan Kettering Monmouth
-
Hoofdonderzoeker:
- Alan L. Ho
-
Contact:
- Site Public Contact
- Telefoonnummer: 212-639-7592
-
Montvale, New Jersey, Verenigde Staten, 07645
- Werving
- Memorial Sloan Kettering Bergen
-
Hoofdonderzoeker:
- Alan L. Ho
-
Contact:
- Site Public Contact
- Telefoonnummer: 212-639-7592
-
-
New York
-
Commack, New York, Verenigde Staten, 11725
- Werving
- Memorial Sloan Kettering Commack
-
Hoofdonderzoeker:
- Alan L. Ho
-
Contact:
- Site Public Contact
- Telefoonnummer: 212-639-7592
-
Harrison, New York, Verenigde Staten, 10604
- Werving
- Memorial Sloan Kettering Westchester
-
Hoofdonderzoeker:
- Alan L. Ho
-
Contact:
- Site Public Contact
- Telefoonnummer: 212-639-7592
-
New York, New York, Verenigde Staten, 10065
- Werving
- Memorial Sloan Kettering Cancer Center
-
Hoofdonderzoeker:
- Alan L. Ho
-
Contact:
- Site Public Contact
- Telefoonnummer: 212-639-7592
-
Uniondale, New York, Verenigde Staten, 11553
- Werving
- Memorial Sloan Kettering Nassau
-
Hoofdonderzoeker:
- Alan L. Ho
-
Contact:
- Site Public Contact
- Telefoonnummer: 212-639-7592
-
-
Ohio
-
Cincinnati, Ohio, Verenigde Staten, 45219
- Actief, niet wervend
- University of Cincinnati Cancer Center-UC Medical Center
-
West Chester, Ohio, Verenigde Staten, 45069
- Actief, niet wervend
- University of Cincinnati Cancer Center-West Chester
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Verenigde Staten, 73104
- Werving
- University of Oklahoma Health Sciences Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 405-271-8777
- E-mail: ou-clinical-trials@ouhsc.edu
-
Hoofdonderzoeker:
- Minh Phan
-
Tulsa, Oklahoma, Verenigde Staten, 74146
- Geschorst
- Oklahoma Cancer Specialists and Research Institute-Tulsa
-
-
Oregon
-
Ontario, Oregon, Verenigde Staten, 97914
- Geschorst
- Saint Alphonsus Cancer Care Center-Ontario
-
Portland, Oregon, Verenigde Staten, 97213
- Werving
- Providence Portland Medical Center
-
Hoofdonderzoeker:
- Dan S. Zuckerman
-
Contact:
- Site Public Contact
- Telefoonnummer: 503-215-2614
- E-mail: CanRsrchStudies@providence.org
-
Portland, Oregon, Verenigde Staten, 97225
- Werving
- Providence Saint Vincent Medical Center
-
Hoofdonderzoeker:
- Dan S. Zuckerman
-
Contact:
- Site Public Contact
- Telefoonnummer: 503-215-2614
- E-mail: CanRsrchStudies@providence.org
-
-
South Carolina
-
Charleston, South Carolina, Verenigde Staten, 29425
- Werving
- Medical University of South Carolina
-
Contact:
- Site Public Contact
- Telefoonnummer: 843-792-9321
- E-mail: hcc-clinical-trials@musc.edu
-
Hoofdonderzoeker:
- John M. Kaczmar
-
-
Washington
-
Seattle, Washington, Verenigde Staten, 98122
- Werving
- Swedish Medical Center-First Hill
-
Hoofdonderzoeker:
- Dan S. Zuckerman
-
Contact:
- Site Public Contact
- Telefoonnummer: 206-215-2343
- E-mail: PCRC-NCORP@Swedish.org
-
-
Wisconsin
-
Mukwonago, Wisconsin, Verenigde Staten, 53149
- Werving
- ProHealth D N Greenwald Center
-
Contact:
- Site Public Contact
- E-mail: research.institute@phci.org
-
Hoofdonderzoeker:
- Timothy R. Wassenaar
-
Oconomowoc, Wisconsin, Verenigde Staten, 53066
- Werving
- ProHealth Oconomowoc Memorial Hospital
-
Hoofdonderzoeker:
- Timothy R. Wassenaar
-
Contact:
- Site Public Contact
- Telefoonnummer: 262-928-7878
-
Waukesha, Wisconsin, Verenigde Staten, 53188
- Werving
- ProHealth Waukesha Memorial Hospital
-
Hoofdonderzoeker:
- Timothy R. Wassenaar
-
Contact:
- Site Public Contact
- Telefoonnummer: 262-928-7632
-
Waukesha, Wisconsin, Verenigde Staten, 53188
- Werving
- UW Cancer Center at ProHealth Care
-
Hoofdonderzoeker:
- Timothy R. Wassenaar
-
Contact:
- Site Public Contact
- Telefoonnummer: 262-928-5539
- E-mail: Chanda.miller@phci.org
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
-
PRIOR TO STEP 1 REGISTRATION:
-
Pathologically (histologically or cytologically) proven diagnosis of nasopharyngeal carcinoma (NPC) that has recurred locoregionally and/or is present at distant sites. Patients who present with metastatic disease (de novo) at diagnosis are also eligible. For locoregional recurrence, the disease must not be amenable to potentially curative surgery or re-irradiation. Eligible patient must have the following characteristics:
- Tumor showing (histological/cytological) Epstein-Barr encoded ribonucleic acid (EBER)-positivity (e.g., In situ hybridization, immunohistochemistry) or
- A known history of detectable plasma EBV DNA (via a polymerase chain reaction [PCR]-based assay) at any time point since the initial diagnosis of NPC.
-
Measurable disease as defined by RECIST 1.1 criteria. Lesion(s) that have been irradiated previously can be counted as measurable as long as radiological progression after the prior radiation therapy has been demonstrated.
- Contrast enhanced CT scan of the chest. The contrast enhanced CT component of a whole-body PET-CT is also acceptable. The plain (non-contrast) CT component of a PET-CT is not acceptable.
- CT the abdomen and pelvis, if clinically indicated (diagnostic quality with contrast, unless contraindicated).
- Patients with known locoregional disease must have contrast enhanced MRI or CT of the nasopharynx and neck as this disease site(s) may be assessed as target lesions. For patients without known locoregional disease, imaging of the nasopharynx and neck is optional.
- Symptomatic and active brain metastases and/or leptomeningeal metastasis on CT and/or MRI imaging: Patients who have prior therapies for brain and leptomeningeal metastasis or cord/cauda compression who are clinically stable for >= 2 months prior to registration and have discontinued systemic steroids therapy (> 10 mg/day prednisone or equivalent) > 4 weeks prior to registration are eligible.
- Patients with base of skull involvement by NPC are allowed unless their disease is directly invading the brain parenchyma, associated with clinical symptoms and/or significant vasogenic edema on radiological imaging.
-
Age >= 18 years.
-
Eastern Cooperative Oncology Group (ECOG) (Zubrod) performance status of 0-2.
-
Negative urine or serum pregnancy test (in persons of childbearing potential) within 14 days prior to registration. Childbearing potential is defined as any person who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal.
-
Absolute neutrophil count (ANC) >= 1500 cells/mm^3.
-
Platelets >= 100,000 cells/mm^3.
-
Hemoglobin (Hgb) >= 8.0 g/dL (Transfusion is accepted. Erythropoietin dependency not accepted.).
-
Total bilirubin =< 1.5 × institutional upper limit of normal (ULN) or direct bilirubin =< ULN for patients with total bilirubin levels > 1.5 × ULN. Patients with known Gilbert's disease who have serum bilirubin level =< 3 × ULN may be enrolled.
-
Alanine transaminase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 3 × ULN (=< 5 × ULN for patients with liver metastases).
-
Serum creatinine =< 1.5 × ULN or calculated creatinine clearance (CrCl) based on Cockcroft-Gault equation >= 30 mL/min for patients with serum creatinine levels > 1.5 × ULN. Cisplatin or carboplatin may be used at the discretion of the investigator - except for patients with CrCl between 30-50 mL/min, for whom carboplatin should be used instead of cisplatin. CrCl must be > 50 mL/min for cisplatin to be used.
-
Albumin-adjusted calcium level based on corrected calcium equation =< 1.5 × ULN (patients are allowed to have treatment for hypercalcemia prior to starting treatment).
-
No prior systemic treatment of palliative intent for recurrent/metastatic (R/M) NPC including cytotoxic chemotherapy. Prior treatment for non-recurrent and non-metastatic NPC is allowed. Systemic therapy given prior to curative intent re-irradiation or surgery is allowed for potentially curable locoregional recurrence.
-
No prior treatment with a PD-1 inhibitor (except if given as adjuvant or neoadjuvant therapy for NPC), PD-L1 inhibitor, anti-PD-L2 inhibitor, LAG-3 inhibitor, CTLA-4 inhibitor (except if given as adjuvant or neoadjuvant therapy for non-recurrent and non-metastatic NPC), or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways.
-
The interval between the last dose of curative-intent treatment for non-recurrent, non-metastatic NPC, including definitive radiotherapy (RT) and/or induction, concurrent, or adjuvant chemotherapy and recurrence must be ˃ 6 months.
-
Clinically significant toxicities from any prior systemic therapy or radiotherapy must have resolved to grade 0 or 1 as per National Cancer Institute (NCI) CTCAE v 5.0 - except alopecia, dry mouth, dysgeusia, dysphagia, and fatigue. Patients with a history of grade 3-4 cisplatin related neuropathy must have recovered to grade 0-2 prior to registration. Patients with a history of hearing impairment, or ototoxicity from prior cisplatin, of any grade are allowed.
-
No prior palliative RT within 30 days prior to registration unless the irradiated site(s) are not the target lesions. The irradiated site(s) also must not be the only sites of measurable recurrent disease.
-
No major surgical procedures within 30 days prior to registration.
-
No history of unstable angina requiring hospitalization within the last 6 months.
-
No history of myocardial infarction within the last 6 months.
-
New York Heart Association Functional Classification II or better (New York Heart Association [NYHA] Functional Classification III/IV are not eligible). Patients with symptomatic coronary artery disease, congestive heart failure or a known history of having a left ventricular ejection fraction < 50% must be stably controlled with medication in the opinion of the treating physician, in consultation with a cardiologist if appropriate.
-
No prior history of myocarditis.
-
No active infection requiring IV antibiotics, IV antiviral, or IV antifungal treatments at the time of study registration.
-
No history of (non-infectious) pneumonitis that required steroids or current pneumonitis requiring steroids and/or immunosuppressive therapy, idiopathic pulmonary fibrosis, drug-induced pneumonitis, organizing pneumonia (i.e., bronchiolitis obliterans), or idiopathic pneumonitis.
-
No history of multi-drug resistant mycobacterium tuberculosis (TB) or active TB, as defined by systemic treatment received =< 2 years prior to registration. Note: Patients who had a history of treated TB ˃ 2 years prior to registration are allowed.
-
No prior solid organ transplant or bone marrow transplant.
-
No conditions requiring systemic treatment with either immunosuppressive doses of corticosteroids (> 10 mg daily prednisone or equivalents) or other immunosuppressive medications within 14 days of registration. Inhaled or topical steroids and adrenal replacement doses < 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease. Steroid premedication for the prophylaxis of CT contrast-related allergies is allowed. The use of dexamethasone as an anti-emetic premedication prior to chemotherapy is also allowed.
-
No active autoimmune disease requiring systemic treatment (i.e., disease modifying agents, corticosteroids, or immunosuppressive drugs) within the past 2 years. These may include (but not limited to) patients with a history of immune-related neurologic disease, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome, myasthenia gravis; systemic autoimmune disease such as systemic lupus erythematosus (SLE), rheumatoid arthritis, connective tissue diseases, scleroderma, inflammatory bowel disease (IBD), Crohn's disease, ulcerative colitis, autoimmune hepatitis, glomerulonephritis; and patients with a history of toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome, or phospholipid syndrome.
- Note: Patients are permitted to enroll if they have vitiligo; type I diabetes mellitus; hypothyroidism, pituitary or adrenal insufficiency requiring only hormone replacement; alopecia; and/or psoriasis not requiring systemic treatment. Conditions not expected to recur in the absence of an external trigger are permitted to enroll.
-
No prior live vaccine within 30 days prior to registration. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster, yellow fever, rabies, Bacillus Calmette-Guerin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., FluMist [registered trademark]) are live attenuated vaccines and are not allowed. Coronavirus disease 2019 (COVID-19) vaccines that are approved by the local drug regulatory authority of the participating region are allowed.
-
No known history of grade 3-4 allergic reaction or hypersensitivity reaction to cisplatin, carboplatin, or gemcitabine.
-
No known history of grade 4 hypersensitivity (or infusion) reaction to any monoclonal antibody. Patients who had prior grade 3 hypersensitivity (or infusion) reaction but could tolerate resumption of the antibody treatment after appropriate pre-medication are eligible.
-
PRIOR TO STEP 2 REGISTRATION:
-
Collection of plasma EBV DNA at baseline is mandatory for all patients prior to Step 2 registration and induction treatment.
- Note: Submission of the baseline sample will be batch shipped.
-
PRIOR TO STEP 3 REGISTRATION/RANDOMIZATION: PATIENTS WITHOUT PROGRESSIVE DISEASE (PD) ONLY:
-
All patients must have received minimum of 3 cycles, and up to a maximum of 6 cycles of induction treatment within 20 weeks from cycle 1, day 1 of induction treatment (i.e., patients must have completed all induction treatment within 20 weeks from cycle 1 day 1, including the treatment breaks). Patients must have completed 6 cycles of induction treatment, except in the following circumstances:
- Significant dose delays as a result of treatment-related toxicities.
- Intercurrent illness(s), that rendered the patient unable to continue induction treatment.
- Note: If a patient received < 6 cycles of induction treatment for reasons other than the above circumstances, they will not be eligible for randomization.
-
A CT scan within 30 days prior to Step 3 registration/randomization is required. If the most recent scan performed is not within this time frame, a repeat scan is required to assess response.
-
Did not meet any criteria that result in permanent discontinuation of study treatment during induction treatment phase.
-
Must meet the criteria for starting/resuming a new cycle of maintenance treatment.
-
Did not experience any nivolumab-related autoimmune toxicities that would result in permanent discontinuation of nivolumab during the induction treatment phase.
-
Collection of the plasma EBV DNA post-induction treatment is mandatory.
- Note: Submission of the post-induction sample will be batch shipped.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Sequentiële toewijzing
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Actieve vergelijker: Arm I (Nivolumab)
Patients receive nivolumab IV over 30 minutes. Cycles repeat every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI on study. Patients also undergo PET/CT or bone scan as clinically indicated. |
Undergo MRI
Andere namen:
Given IV
Andere namen:
Undergo CT or PET/CT
Andere namen:
Undergo PET/CT
Andere namen:
Undergo bone scan
Andere namen:
|
|
Experimenteel: Arm II (Nivolumab, relatlimab)
Patients receive nivolumab IV over 30 minutes and relatlimab IV over 30-90 minutes. Cycles repeat every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI on study. Patients also undergo PET/CT or bone scan as clinically indicated. |
Undergo MRI
Andere namen:
Given IV
Andere namen:
Undergo CT or PET/CT
Andere namen:
Undergo PET/CT
Andere namen:
Given IV
Andere namen:
Undergo bone scan
Andere namen:
|
|
Experimenteel: Induction therapy (Platinum-gemcitabine-nivolumab)
Patients receive nivolumab IV over 30 minutes on day 1 of each cycle, cisplatin IV or carboplatin IV over 30-60 minutes on day 1 of each cycle and gemcitabine IV over 30 minutes on days 1 and 8 of each cycle. Cycles repeat every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI and blood sample collection during screening and on study. |
Given IV
Andere namen:
Given IV
Andere namen:
Undergo blood sample collection
Andere namen:
Undergo MRI
Andere namen:
Given IV
Andere namen:
Undergo CT or PET/CT
Andere namen:
Given IV
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Progression-free survival (PFS)
Tijdsspanne: Time from randomization to progressive disease (PD) or death due to any cause, assessed up to 6 years
|
Will be assessed in both treatment arms and will be estimated using the Kaplan-Meier method. The comparison of PFS distributions between treatment arms will be performed using the log-rank test. Additional analyses of treatment effect will be performed using Cox models with the stratification factors included as a fixed covariates, as well as other tumor and patient characteristics, listed below. Median PFS and the corresponding 95% confidence intervals (CIs) for each arm will be estimated with the Brookmeyer-Crowley method. Multivariable analysis will be performed using a Cox proportional hazards model and relevant patient and tumor characteristics (country [Asian sites versus (vs.) Non-Asian sites], keratinizing squamous carcinoma, sex, age, and baseline Epstein-Barr virus (EBV) deoxyribonucleic acid [DNA]). Hazard ratios and their respective 85% lower confidence bound, and 95% confidence intervals will be provided. |
Time from randomization to progressive disease (PD) or death due to any cause, assessed up to 6 years
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Overall survival (OS)
Tijdsspanne: Time from randomization to death due to any cause, assessed up to 6 years
|
Will be estimated using the Kaplan-Meier method and between-arm differences will be assessed using the log-rank test. Median OS and the corresponding 95% CIs using log-log transformation to survival function for each arm will be estimated with the Brookmeyer-Crowley method. |
Time from randomization to death due to any cause, assessed up to 6 years
|
|
Tumor response
Tijdsspanne: Up to 6 years
|
Will be assessed using Response Evaluation Criteria in Solid Tumors version 1.1. Cox proportional hazards models will be used to determine hazard ratios (cause-specific hazard ratios in the case of endpoints with competing risks) and to assess the effects of covariates of interest. Fine-Gray sub-distribution hazards Cox model will be used to complement the competing risk analyses. |
Up to 6 years
|
|
Locoregional failure
Tijdsspanne: Up to 6 years
|
Cox proportional hazards models will be used to determine hazard ratios (cause-specific hazard ratios in the case of endpoints with competing risks) and to assess the effects of covariates of interest. Fine-Gray sub-distribution hazards Cox model will be used to complement the competing risk analyses. |
Up to 6 years
|
|
Distant metastasis
Tijdsspanne: Up to 6 years
|
Cox proportional hazards models will be used to determine hazard ratios (cause-specific hazard ratios in the case of endpoints with competing risks) and to assess the effects of covariates of interest. Fine-Gray sub-distribution hazards Cox model will be used to complement the competing risk analyses. |
Up to 6 years
|
|
Incidence of adverse events (AEs)
Tijdsspanne: Up to 6 years
|
Will be graded using Common Terminology Criteria for Adverse Events version 5.0. Counts of all AEs by grade will be provided by treatment arm. Counts and frequencies will be provided for the worst grade AE experienced by the patient by treatment arm. The rate of patients with at least 1 grade 3 or higher AE will be compared between the treatment arms using a chi-square test for proportions and confidence intervals for rate difference will be computed using Miettinen-Nurminen (score) method |
Up to 6 years
|
|
Post-induction plasma EBV DNA as a prognostic biomarker
Tijdsspanne: Up to 6 years
|
Will be defined as a binary biomarker (detectable: >= 1 copies/mL vs. undetectable: 0 copies/mL). Biomarker effect HRs from multivariable Cox models, including key tumor and patient characteristics will also be reported. |
Up to 6 years
|
|
Pre-induction plasma EBV DNA vs. progressive disease (PD) during induction treatment
Tijdsspanne: Up to 6 years
|
Will include all patients treated with concurrent (induction) treatment and a binary biomarker based on pre-induction plasma EBV DNA (< 2000 vs. ≥2000 copies/mL). PD rates during induction for each biomarker subgroup will be computed assuming a binomial distribution and compared between biomarker subgroups using a chi-square test. Multivariable Cox models, including key tumor and patient characteristics will also be included. |
Up to 6 years
|
|
Persistent plasma EBV DNA vs. PFS
Tijdsspanne: Up to 6 years
|
Will examine the association between persistent EBV DNA after induction treatment and PFS. Only randomized patients with positive pre-induction plasma EBV DNA will be included (~90-95%). Patients will be classified into "EBV DNA positive to negative" and "EBV DNA consistently positive" based on the pre-induction and post-induction EBV DNA. Multivariable Cox models, including key tumor and patient characteristics will also be included. |
Up to 6 years
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Post-induction EBV DNA as a predictive biomarker
Tijdsspanne: Up to 6 years
|
Will be assessed of the predictive role of post-induction EBV DNA on PFS and OS will be performed using the binary biomarker. Cox proportional hazards model with treatment arm, binary biomarker, and its interaction will be used for these analyses. Treatment effect hazard ratios and 95% confidence intervals will be reported. Adjusted HR estimates will be obtained after adding key patient and tumor characteristics. |
Up to 6 years
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Brigette B Ma, NRG Oncology
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Stomatognatische ziekten
- Neoplasmata per site
- Neoplasmata
- Neoplasmata per histologisch type
- Hoofd- en nekneoplasmata
- Neoplasmata, glandulair en epitheel
- Carcinoom
- KNO-ziekten
- Faryngeale neoplasmata
- Otorinolaryngologische neoplasmata
- Nasofaryngeale ziekten
- Faryngeale ziekten
- Nasofaryngeale neoplasmata
- Nasofarynxcarcinoom
- Aminozuren, peptiden en eiwitten
- Eiwitten
- Zwavelverbindingen
- Organische chemicaliën
- Heterocyclische verbindingen, 1-ring
- Heterocyclische verbindingen
- Onderzoekstechnieken
- Klinische laboratoriumtechnieken
- Diagnostische technieken en procedures
- Diagnose
- Antilichamen, monoklonaal, gehumaniseerd
- Antilichamen, monoklonaal
- Antilichamen
- Immunoglobulinen
- Immunoproteïnen
- Bloedeiwitten
- Serum -globulines
- Globulines
- Anorganische chemicaliën
- Chloorverbindingen
- Stikstofverbindingen
- Coördinatiecomplexen
- Deoxycytidine
- Cytidine
- Pyrimidine -nucleosiden
- Pyrimidines
- Elementen
- Metalen
- Chemie -technieken, analytisch
- Spectrumanalyse
- Metalen, zwaar
- Immunoglobuline -isotypes
- Sulfiden
- Anionen
- Ionen
- Elektrolyten
- Waterstofsulfide
- Platinumverbindingen
- Overgangselementen
- Nivolumab
- Gemcitabine
- Carboplatine
- Immunoglobuline G
- Cisplatine
- 1,2-diaminocyclohexaanplatina II-citraat
- Exemplaarbehandeling
- Magnetische resonantiespectroscopie
- Disulfides
- Platina
- relatlimab
Andere studie-ID-nummers
- NCI-2023-06678
- U10CA180868 (Subsidie/contract van de Amerikaanse NIH)
- NCI-2023-06678 (Register-ID: CTRP (Clinical Trial Reporting Program))
- NRG-HN011 (Andere identificatie: CTEP)
- NRG-HN011 (Andere identificatie: NRG Oncology)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .